Al Musaimi Othman
School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK.
Antibiotics (Basel). 2025 Feb 7;14(2):166. doi: 10.3390/antibiotics14020166.
Since 1955, a total of 12 peptide-based drugs with antimicrobial or antifungal properties have received approval from the Food and Drug Administration (FDA). Peptides present a promising opportunity to address serious infections that may be challenging to manage through other means. Peptides exhibit the capability to leverage various mechanisms, and in some cases, multiple mechanisms are employed for this purpose. Despite the initial approval dating back to 1955, the FDA recently approved an echinocandin peptide just last year. The ongoing approvals underscore the significance of peptides in addressing ongoing medical challenges. Approximately 22 peptide therapeutics with an antibacterial and antifungal spectrum are currently undergoing various phases of clinical trials, showing promising results. In this review, antimicrobial and antifungal peptides are analyzed in terms of their chemical structure, indication, mode of action, and development journey, concluding with their arrival in the pharmaceutical market.
自1955年以来，共有12种具有抗菌或抗真菌特性的肽类药物获得了美国食品药品监督管理局（FDA）的批准。肽为解决那些可能难以通过其他方式控制的严重感染提供了一个有前景的机会。肽具有利用多种机制的能力，在某些情况下，为此会采用多种机制。尽管最初的批准可追溯到1955年，但FDA去年才刚刚批准了一种棘白菌素肽。持续的批准凸显了肽在应对当前医学挑战方面的重要性。目前约有22种具有抗菌和抗真菌谱的肽类疗法正处于临床试验的各个阶段，显示出有前景的结果。在这篇综述中，对抗菌和抗真菌肽从其化学结构、适应症、作用方式和研发历程方面进行了分析，并以它们进入药品市场作为总结。
